SH-1028

DRUG4 trials

Sponsors

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Conditions

Advanced Solid CancerHealthy Male VolunteersNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC

Nanjing Sanhome Pharmaceutical, Co., Ltd.Non-small Cell Lung Cancer

Start: 2018-04-25End: 2019-12-31Target: 85Updated: 2019-01-28

Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

Nanjing Sanhome Pharmaceutical, Co., Ltd.Advanced Solid Cancer

Start: 2018-09-13End: 2019-12-31Target: 14Updated: 2019-01-29

The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028

Nanjing Sanhome Pharmaceutical, Co., Ltd.Healthy Male Volunteers

Start: 2021-04-06End: 2021-06-30Target: 40Updated: 2021-03-22

Phase 2

A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

Nanjing Sanhome Pharmaceutical, Co., Ltd.Non-Small Cell Lung Cancer

Start: 2019-03-31End: 2021-03-31Target: 300Updated: 2019-02-01

Related Papers

Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.

2022-07-0515 citations